0001193125-20-031546.txt : 20200211 0001193125-20-031546.hdr.sgml : 20200211 20200211172233 ACCESSION NUMBER: 0001193125-20-031546 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200211 DATE AS OF CHANGE: 20200211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Unity Biotechnology, Inc. CENTRAL INDEX KEY: 0001463361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264726035 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-90777 FILM NUMBER: 20598159 BUSINESS ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (415) 328-5504 MAIL ADDRESS: STREET 1: 3280 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Cenexys, Inc. DATE OF NAME CHANGE: 20130703 FORMER COMPANY: FORMER CONFORMED NAME: Forge Inc DATE OF NAME CHANGE: 20090504 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: David Nathaniel E CENTRAL INDEX KEY: 0001559531 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: C/O KYTHERA BIOPHARMACEUTICALS, INC. STREET 2: 27200 WEST AGOURA ROAD, SUITE 200 CITY: CALABASAS STATE: CA ZIP: 91301 SC 13G 1 d855136dsc13g.htm SC 13G SC 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )*

 

 

Unity Biotechnology, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

91381U 101

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

Page 1 of 5 pages.

CUSIP No. 91381U 101    13G   

 

  1.   

Name of Reporting Person

I.R.S. Identification No. of Above Persons (Entities Only)

 

Nathaniel E. David

  2.  

Check the Appropriate Box if a Member of a Group

(a)  ☐        (b)  ☐

 

  3.  

SEC Use Only

 

  4.  

Citizenship or Place of Organization

 

United States of America

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5.    

Sole Voting Power

 

2,372,160 shares

   6.   

Shared Voting Power

 

-0- shares

   7.   

Sole Dispositive Power

 

2,372,160 shares

   8.   

Shared Dispositive Power

 

-0- shares

  9.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,372,160 shares

10.  

Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

☐

11.  

Percent of Class Represented by Amount in Row (9)

 

5.15%

12.  

Type of Reporting Person

 

IN

 

Page 2 of 5 pages.

Item 1.

 

  (a)

Name of Issuer:

Unity Biotechnology, Inc. (“Unity”)

 

  (b)

Address of Issuer’s Principal Executive Offices:

285 East Grand Avenue

South San Francisco, CA 94080

Item 2.

 

  (a)

Name of Persons Filing:

Nathaniel E. David

 

  (b)

Address of Principal Business Office:

The principal business office for all persons filing is:

c/o Unity Biotechnology, Inc.

285 East Grand Avenue

South San Francisco, CA 94080

 

  (c)

Citizenship:

Nathaniel E. David is a U.S. citizen.

 

  (d)

Title of Class of Securities:

Common Stock, $0.0001 par value per share

 

  (e)

CUSIP Number:

91381U 101

 

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

 

Item 4.

Ownership.

 

  (a)

Amount Beneficially Owned:

Nathaniel E. David:    2,372,160 shares

 

Page 3 of 5 pages.

  (b)

Percent of Class:

Nathaniel E. David:    5.15%

The percentage for Mr. David is calculated using a denominator of 45,941,750 outstanding shares as of November 1, 2019 as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, plus 93,504 shares that could be acquired within 60 days of December 31, 2019.

 

  (c)

Number of shares as to which such person has:

 

  (i)

Sole power to vote or direct the vote: 2,372,160

 

  (ii)

Shared power to vote or direct the vote: 0

 

  (iii)

Sole power to dispose or direct the disposition of: 2,372,160

 

  (iv)

Shared power to dispose or direct the disposition of: 0

 

Item 5.

Ownership of Five Percent or Less of a Class.

Not Applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

 

Item 9.

Notice of Dissolution of Group.

Not Applicable.

 

Item 10.

Certification.

Not Applicable.

 

Page 4 of 5 pages.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 11, 2020       /s/ Nathaniel E. David
      Nathaniel E. David

 

Page 5 of 5 pages.